L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
AssigneeThe Texas A&M University System
InventorsJonathan T. Sczepanski, Charles E. Deckard
Life of this patent
Estimating the term…
Abstract
The present invention contemplates a method for the treatment of cancer comprising L-nucieic acid. The present invention contemplates a method for the treatment of cancer comprising guanosine-rich L-oligonucleotides. The present invention also relates to Polycomb Repressive Complex 2 (PRC 2) 1, -oligonucleotide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyl transferase activity.
Claims61
A method of treatment of a subject with a condition related to aberrant PRC2 methyltransferase activity comprising:
- (a) providing:
- (i) L-nucleic acid, and
- (b) treating said subject with said L-nucleic acid.
A method of treating cancer, comprising:
- a) providing i) a subject with cancer, said cancer overexpressing PRC2 and ii) a composition comprising L-nucleic acids;
- and b) administering said composition to said subject.
A method of screening, comprising a) providing cancer cells ex vivo, said cancer cells overexpressing PRC2 and ii) at least two different L-nucleic acids;
- and b) testing said at least two different L-nucleic acids for inhibition of PRC2 by exposing said cancer cells to said L-nucleic acids.
Dependencies are inferred from the claim text.